Oncolytics Biotech Inc. Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Feb 14, 2025 · CIK: 1129928

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, corporate-filing

TL;DR

ONCOLYTICS BIOTECH INC (ONCO) filed a 6-K on 2/14/25. Standard foreign private issuer update.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on February 14, 2025, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and its principal executive offices are located at Suite 804, 322 11th Avenue SW, T2R 0C5. Oncolytics Biotech Inc. is listed under the Pharmaceutical Preparations industry (SIC 2834) and has a SEC file number of 001-38512.

Why It Matters

This filing provides routine corporate information for investors and regulators, confirming the company's status and location as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain new material financial or operational information that would typically increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of February 2025.

What is the company's SEC file number?

The SEC file number for Oncolytics Biotech Inc. is 001-38512.

Where is Oncolytics Biotech Inc. located?

Oncolytics Biotech Inc. is located in Calgary, Alberta, Canada, with principal executive offices at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

Does the company file an annual report under Form 20-F or 40-F?

The registrant indicates it files annual reports under cover of Form 20-F.

What is the Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc.?

The Standard Industrial Classification code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-02-14 17:16:33

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date February 14, 2025 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing